Drug
KH902 fusion protein clinical trials
Also written Conbercept and KH902.
- studies test it
- 20
- open now
- 1
- in phase 3
- 1
- first study started
- 2010
Keep track of what changes. Save the KH902 fusion protein studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 1
- Phase 2
- 9
- Phase 3
- 1
- Phase 4
- 3
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 12
Chengdu Kanghong Biotech Co., Ltd. (7) · Ruijin Hospital (2) · Sun Yat-sen University (2) · Shanghai Eye Disease Prevention and Treatment Center (1) · Bojie Hu (1) · RemeGen Co., Ltd. (1) · Tianjin Medical University Eye Hospital (1) · Wang Yusheng (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses KH902 fusion protein is read from its arms, and is right about nine times in ten.
Testing it · 20
- Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyRecruitingNot applicableWang YushengNCT06717412Written as Conbercept
- Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab InjectionCompletedNot applicableBojie HuNCT07144865Written as conbercept ophthalmic injection （0.5mg）
- Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic RetinopathyActive, not recruitingPhase 4Shanghai Eye Disease Prevention and Treatment CenterNCT06305143Written as Conbercept
- Evaluation of RC28-E Injection in Diabetic Macular EdemaCompletedPhase 2RemeGen Co., Ltd.NCT04782115Written as Conbercept
- Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR PatientsStatus unknownPhase 2Peking University Third HospitalNCT05642793Written as proactive Anti-VEGF (conbercept) use
- A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT04990271Written as Conbercept ophthalmic injection
- Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)Status unknownNot applicableZhongshan Ophthalmic Center, Sun Yat-sen UniversityNCT04627402Written as Conbercept and TA
- Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line TherapyStatus unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT04555304Written as KH903 + Paclitaxel
- Conbercept Injection in Treatment of Severe Proliferative Diabetic RetinopathyCompletedPhase 4Ruijin HospitalNCT02816710Written as Conbercept
- Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal HaemangiomaStatus unknownEarly Phase 1Sun Yat-sen UniversityNCT03973125Written as conbercept
- Intravitreal Conbercept After VitrectomyCompletedEarly Phase 1Tianjin Medical University Eye HospitalNCT03426540Written as Conbercept
- PRP vs PRP+IVC for Severe nPDRStatus unknownNot applicableRuijin HospitalNCT03863535Written as Conbercept
- Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal HaemangiomaStatus unknownEarly Phase 1Sun Yat-sen UniversityNCT03571282Written as conbercept
- The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)Status unknownPhase 4Chengdu Kanghong Biotech Co., Ltd.NCT03159884Written as Conbercept
- Conbercept in Choroidal Neovascularization Secondary to UveitisStatus unknownPhase 2Chongqing Medical UniversityNCT02934841Written as Conbercept
- Intravitreal Conbercept for Idiopathic Choroidal NeovascularizationStatus unknownPhase 2Jiao MingfeiNCT02857517Written as conbercept
- Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)Status unknownPhase 3Chengdu Kanghong Biotech Co., Ltd.NCT02194634Written as Conbercept
- An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)Status unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT02098720Written as Conbercept
- Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein OcclusionStatus unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT01809236Written as Conbercept
- Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)CompletedPhase 1/2Chengdu Kanghong Biotech Co., Ltd.NCT01324869Written as KH902
Given in every arm · 2 — KH902 fusion protein is usual care beside what is tested
- Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular DegenerationStatus unknownPhase 4Xiaodong SunNCT02802657Written as Conbercept
- Initial Versus Delayed PDT Combination With Conbercept in PCVCompletedPhase 4The Eye Hospital of Wenzhou Medical UniversityNCT02821520Written as conbercept
As the comparator · 1 — what is tested is compared with KH902 fusion protein
Codes
What other systems call KH902 fusion protein · ClinicalTrials.gg INT005241
- MeSH (NLM) C527363KH902 fusion proteinOne source NLM
- UNII (FDA) 1P05PW62F3CONBERCEPTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527363 | KH902 fusion protein | One source NLM |
| UNII (FDA) | 1P05PW62F3 | CONBERCEPT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.